浏览全部资源
扫码关注微信
1.上海交通大学医学院附属仁济医院(上海 200127)
2.海军军医大学第一附属医院(上海长海医院)(上海 200433)
3.上海中医药大学附属岳阳中西医结合医院(上海 200437)
4.上海中医药大学附属龙华医院(上海 200032)
李鹤,主任医师,博士研究生导师; E-mail:lihe1972@hotmail.com
纸质出版日期:2024-06-10,
收稿日期:2024-04-17,
扫 描 看 全 文
李鹤,茹丹,周艳,等.中西医结合治疗卵巢癌骨髓抑制临床诊疗专家共识[J].上海中医药杂志,2024,58(增刊1):22-29.
LI He,RU Dan,ZHOU Yan,et al.Expert consensus on clinical diagnosis and treatment of myelosuppression in ovarian cancer with integrated Chinese and Western medicine[J].Shanghai Journal of Traditional Chinese Medicine,2024,58(增刊1):22-29.
李鹤,茹丹,周艳,等.中西医结合治疗卵巢癌骨髓抑制临床诊疗专家共识[J].上海中医药杂志,2024,58(增刊1):22-29. DOI: 10.16305/j.1007-1334.2024.05.
LI He,RU Dan,ZHOU Yan,et al.Expert consensus on clinical diagnosis and treatment of myelosuppression in ovarian cancer with integrated Chinese and Western medicine[J].Shanghai Journal of Traditional Chinese Medicine,2024,58(增刊1):22-29. DOI: 10.16305/j.1007-1334.2024.05.
卵巢癌骨髓抑制海派中医妇科中西医结合专家共识
myelosuppression in ovarian cancerShanghai style traditional Chinese medicine gynecologyintegration of traditional Chinese and Western medicineexpert consensus
FRIEDRICH M, FRIEDRICH D, KRAFT C, et al. Multimodal treatment of primary advanced ovarian cancer[J]. Anticancer Res, 2021, 41(7): 3253-3260.
CRAWFORD J, DALE D C, LYMAN G H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management[J]. Cancer, 2004, 100(2): 228-237.
LYMAN G H, ABELLA E, PETTENGELL R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review[J]. Crit Rev Oncol Hematol, 2014, 90(3): 190-199.
王炳胜,李永申,彭东长,等. 中西医结合治疗重度骨髓抑制疗效观察[J]. 中国中医急症,2006, 15(7): 714-715.
何流,钱志英. 中西医结合防治肿瘤化疗所致骨髓抑制的临床研究[J]. 肿瘤研究与临床,2006, 18(6): 411-412.
李万琤,谢守勇. 中西医结合治疗化疗中常见的骨髓抑制反应[J]. 四川中医,2005, 23(9): 18-19.
武迎磊,崔向丽,袁耀辉,等. 抗肿瘤药物引起骨髓抑制的预防及治疗[J]. 药品评价,2010, 7(14): 30-36.
BLAYNEY D W, SCHWARTZBERG L. Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review[J]. Cancer Treat Rev, 2022, 109: 102427.
徐瑞华,石远凯,冯继锋,等. 中国肿瘤化疗相关性血小板减少症专家诊疗共识(2019版)[J]. 中国医学前沿杂志(电子版),2020, 12(1): 51-58.
FORCELLO N P, KHUBCHANDANI S, PATEL S J, et al. Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review[J]. J Oncol Pharm Pract, 2015, 21(2): 148-156.
MACHLUS K R, THON J N, JrITALIANO J E. Interpreting the developmental dance of the megakaryocyte: a review of the cellular and molecular processes mediating platelet formation[J]. Br J Haematol, 2014, 165(2): 227-236.
ZORZI D, LAURENT A, PAWLIK T M, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases[J]. Br J Surg, 2007, 94(3): 274-286.
马军,王杰军,张力,等. 肿瘤相关性贫血临床实践指南 (2015—2016版)[J]. 中国实用内科杂志,2015, 35(11): 921-930.
李笑秋.肿瘤患者贫血发生率及相关因素分析[J]. 中国临床医生杂志,2020, 48(4): 446-447.
宋正波,陆舜,冯继锋,等. 中国肿瘤相关性贫血发生率及治疗现状的流行病学调查研究[J]. 中国肿瘤,2019, 28(9): 718-722.
温灏. PARP抑制剂不良反应管理的中国专家共识(2021年版)[J]. 中国实用妇科与产科杂志,2021, 37(11): 1119-1130.
郭荣霞,高荣美,黄清香,等. 造血干/祖细胞造血记忆机制的研究进展[J]. 中国细胞生物学学报,2022, 44(1):16-23.
ITO K, ITO K. Hematopoietic stem cell fate through metabolic control[J]. Exp Hemato, 2018, 64 : 1-11.
HE M, WANG N, ZHENG W, et al. Ameliorative effects of ginsenosides on myelosuppression induced by chemotherapy or radiotherapy[J]. J Ethnopharmacol, 2021, 268: 113581.
AL-SABAH J, BACCIN C, HAAS S. Single cell and spatial transcript-tomics approaches of the bone marrow microenvironment[J]. Curr Opin Oncol, 2020, 32(2): 146-153.
CRANE G M, JEFFERY E, MORRISON S J. Adult haematopoietic stem cell niches[J]. Nat Rev Immunol, 2017, 17(9): 573-590.
ZHENG P, CHANG X, LU Q, et al. Cytopenia and autoimmune diseases: a vicious cycle fueled by mTOR dysregulation in hematopoietic stem cells[J]. J Autoimmun, 2013, 41: 182-187.
STURGEON C M, DITADI A, AWONG G, et al. Wnt signaling controls the specification of definitive and primitive hematopoiesis from human pluripotent stem cells[J]. Nat Biotechnol, 2014, 32(6): 554-561.
曾妙,黄洋,甘家丽,等. 基于造血干细胞衰老及造血微环境损伤探讨骨髓抑制机制的研究进展[J]. 现代肿瘤医学,2020, 28(22): 3990-3994.
吴仙. 中医疗法对化疗后骨髓抑制干预效果的网状Meta分析[D]. 南昌:江西中医药大学,2023.
0
浏览量
0
下载量
0
CSCD
0
CNKI被引量
关联资源
相关文章
相关作者
相关机构